Story perspectives

Trump's Tylenol Comments Ignite New Autism Lawsuits

9/30/2025

Summary

Story summary

President Trump's comments linking Tylenol to autism spurred renewed lawsuits against Kenvue.
Lawyers report surge in inquiries after Trump's statements and FDA's safety-label update.
Internal emails show Johnson & Johnson, Tylenol's producer until 2023, knew acetaminophen pregnancy risks.
FDA acknowledges links to neurodevelopmental disorders, prompting warnings for pregnant women.
Appeals seek reinstatement of dismissed lawsuits, though causation remains challenging.

History

Historical Context

In 2016, the CDC reported that 1 in 68 children were diagnosed with autism, prompting concerns about environmental factors. This scrutiny intensified in 2025 when President Trump linked acetaminophen use during pregnancy to autism, despite health authorities asserting no causal relationship. Ongoing lawsuits against Johnson & Johnson and Kenvue may reshape drug safety regulations and public trust in pharmaceuticals.

1 of 2

Story summary

President Trump's comments linking Tylenol to autism spurred renewed lawsuits against Kenvue.
Lawyers report surge in inquiries after Trump's statements and FDA's safety-label update.
Internal emails show Johnson & Johnson, Tylenol's producer until 2023, knew acetaminophen pregnancy risks.
FDA acknowledges links to neurodevelopmental disorders, prompting warnings for pregnant women.
Appeals seek reinstatement of dismissed lawsuits, though causation remains challenging.

1 / 2